September 1, 2010 / 3:47 PM / 9 years ago

U.S. to aggressively pursue drug misbranding cases

WASHINGTON, Sept 1 (Reuters) - The U.S. Department of Justice will continue to “aggressively pursue” pharmaceutical companies that illegally market drugs for uses that have not been approved by health regulators, a top agency official said on Wednesday.

“These cases are cases that we will continue to aggressively pursue,” Tony West, assistant attorney general for the Justice Department’s civil division, told reporters after announcing a plea deal with Allergan Inc (AGN.N).

He said the Allergan case, in which the company will pay $600 million in penalties and plead guilty to a misdemeanor charge, creates a deterrent in the industry. (Reporting by Jeremy Pelofsky, editing by Maureen Bavdek)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below